Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 81745

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2022 | Month : August | Volume : 16 | Issue : 8 | Page : DC12 - DC15 Full Version

Effect of Interleukin 28B SNP rs12979860 Genotype on Viral Load in Hepatitis C Virus in Kolar Population, Karnataka, India


Published: August 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/56858.16711
Devinder Kaur, Prabhakar Kamarthy, Subhashis Das

1. PhD Scholar, Department of Microbiology, Sri Devaraj Urs Medical College, Kolar, Karnataka, India. 2. Professor, Department of Medicine, Sri Devaraj Urs Medical College, Kolar, Karnataka, India. 3. Associate Professor, Department of Pathology, Sri Devaraj Urs Medical College, Kolar, Karnataka, India.

Correspondence Address :
Dr. Prabhakar Kamarthy,
Professor, Department of Medicine, Sri Devaraj Urs Medical College, Kolar, Karnataka, India.
E-mail: devinder.dvd@gmail.com

Abstract

Introduction: The natural course of Hepatitis C Virus (HCV) infection is influenced by a number of host and viral variables. Interleukin 28B (IL28B) is a kind of interleukin. A Single Nucleotide Polymorphism (SNP) designated as rs12979860 was reported to predict viral clearance with and without treatment. Subjects with the GG (favourable) IL28B rs12979860 genotype were more likely to clear the infection spontaneously and respond well to therapy. These findings imply that people who have the “favourable” GG genotype have a lower viral burden than those who have the “unfavourable” AA genotype.

Aim: To determine the effect of IL28B SNP rs12979860 genotype on HCV viral load in Kolar population, Karnataka, India.

Materials and Methods: The present study was a case-control study which was carried out in Department of Microbiology, Sri Devaraj Urs Medical College, Kolar, Karnataka, India. Subjects were enrolled from Department of Medicine of R. L. Jalapa Hospital and Research centre, teaching hospital of Sri Devaraj Urs Medical College between November 2020 to March 2021. A total of 248 were taken of which 124 were HCV antibody-positive and 124 were controls. The effect of IL28B rs12979860 SNP on HCV viral load and clearance among HCV-infected patients were examined. Detection and quantification of HCV-RNA was determined by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). IL28B rs12979860 genotyping was performed using PCR and Restriction Fragment Length Polymorphism (RFLP) technique and specific primers. Statistical analysis was done by using open epi tool. The frequency, percentage and Chi-square test were used to analyse categorical variable. A p-value <0.05 was considered as significant.

Results: In this study the frequency of G/G genotype was considerably high 83 (67%) compared to G/A 17 (13.7%) and A/A 24 (19.3%) and in group 2 the frequency of G/G genotype 84 (67.7%), G/A genotype 34 (27.4%) and A/A genotype 6 (4.9%). There was a statistically significant difference in both the HCV infected and healthy controls groups (p=0.002). The average (±SEM) HCV viral load was 4.6±3.6×107, 9.4±7.7×107 and 5.5±5.2×107 IU/mL in patients with the IL28B rs12979860 GG, GA and AA respectively. Also there was a significance between the viral load and IL28B rs 12979860 (p-value <0.05).

onclusion: Thus, present study results indicate that the IL28B rs12979860 genotype has an effect on viral load in untreated HCV patients. These findings highlight the importance of viral-host interactions in influencing the outcome of HCV infection.

Keywords

Infection, Polymorphism, Ribonucleic acid levels

HCV spreads by blood-to-blood contact and is a leading cause of chronic liver disease, with an estimated 170 million people infected worldwide (1). Approximately 18 million individuals in India are assessed to be contaminated with HCV. In 75-85% of infected people, HCV infection is persistent (2). However, 20-40% of people with acute HCV infection obtain spontaneous clearance, the time course and factors that influence clearance remain unclear (3). HCV is a positive-sense single-stranded RNA virus having a place with the family Flaviviridae. Also, SNP at the rs12979860 site of IL28B, also known as interferon λ3, has been used as a predictor of viral clearance with and without therapy (4),(5),(6).

Interferon λ3, coded by the IL28B gene located on Chromosome 19, induces antiproliferative and antiviral activity and also up regulates interferon-stimulated genes, via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway (7). IL28B binds to IL28B receptors on hepatocytes that further activate the JAK-STAT pathway. Then STAT activated by JAK through phosphorylation and up regulation of the Interferon Regulatory Genes (ISGs) that leads to spontaneous clearance of the virus. Several Genome Wide Association Studies (GWAS) have shown that response to Pegylated Interferon/Ribavirin (PEG IFN/RBV) therapy in genotype 1 infections are strongly associated with SNPs within or adjacent to the IL28B gene (rs12979860 and rs8099917) (4),(6),(8). Besides, rs12979860 have genotypes CC, CT and TT, while rs8099917 have genotypes TT, TG and GG. A better treatment response in Chronic Hepatitis C Infection (CHC) has been shown to be associated with C/C genotype at rs12979860 and T/T genotype at rs8099917. In different ethnic groups, better outcomes in the patients who have protective genes have been observed, this is because the efficacy of standard anti-HCV treatment is affected by the SNPs of IL-28 (4),(5). Besides hepatitis C, the role of these polymorphisms and their impact on response has been studied, in a large number of other infectious and non infectious diseases, i.e., human T lymphotropic virus, herpes simplex virus, Human Immunodeficiency Virus (HIV), and cytomegalovirus to name a few (9). In India, IL28B and HCV RNA levels studies are limited (10). Moreover, In Kolar region this was the first study giving evidence about the IL28B and HCV viral loads levels. The link between IL28B SNPs and HCVRNA levels is still challenged. Later IL28B can also compare with HCV genotypes. Therefore, in order to predict the treatment therapy of interferon and clearance rate of HCV infection, understanding IL-28B gene polymorphism is important. The aim of the is to determine the effect of Interleukin 28B SNP rs12979860 genotype on HCV viral load in Kolar population, Karnataka.

Material and Methods

The present study was a case-control study which was carried out in Department of Microbiology, Sri Devaraj Urs Medical College, Kolar, Karnataka, India. The study was approved by Institutional Ethics Committee (IEC) of Sri Devaraj Urs Medical College (DMC/KLR/IEC/467/2020-21).Subjects were enrolled from Department of Medicine between November 2020 to March 2021. Written informed consent was obtained prior to the recruitment of the subjects.

Inclusion criteria: Symptomatic and asymptomatic Hepatitis C infected patients.

Exclusion criteria: HBsAg positive patients, HIV infected patients and pregnant women.

A total number of 248 subjects were enrolled which were further categorised as group 1 and group 2 as follows:

Group 1: (n=124) HCV infected patients were diagnosed by Chemiluminesense Immunoassays (CLIA).

Group 2: (n=124) Healthy controls.

Sample collection: A whole 5 mL of peripheral blood sample was collected from all the HCV positive patients and 3 mL from healthy controls and sample transferred into the sterile tubes containing Chemiluminesense. After centrifugation the plasma was separated and was stored in aliquots at -80°C for further analysis.

RNA extraction: Viral RNA was extracted using QIAamp Viral RNA Mini Kit according to the manufacturer’s instructions (# catalog number 52904 QIAamp Viral RNA mini kit, Qiagen, USA).

DNA extraction for IL28B genotyping: The blood sample was further processed for Deoxyribonucleic Acid (DNA) extraction by using manual method i.e. salting out method (11). Whole blood was treated with Erythrocyte Lysate Buffer (ELB) and Red Blood Cells (RBCs) were lysed. Total isolated White Blood Cells (WBCs) pellets were exposed to proteinase K for protein digestion and further DNA was extracted. The genomic DNA was used to check the IL28B polymorphism (rs12979860).

qPCR viral load detection: quantitative PCR was performed for the detection of HCV RNA using HCV-K-004 kit (CoSara diagnostics. Pvt. Ltd) by quantitative qPCR by using Magnetic Induction Cycler - qPCR (Mic-qPCR, biomolecular systems). The HCV viral load kit included reagents and a readymade master mix with internal positive control along with five standards. The negative control was included in parallel for each batch of analysis. The single-step reverse transcription real-time PCR transcribes and amplifies conserved sequence of RNA from the 5’ untranslated region of HCV genome was detected by using Quasar 670 dye (Q670). A human RNase P gene marker was used as an internal positive control to check the reliability of each reaction, and the CAL Fluor Red 610 dye was being used to detect inadequate samples (CF610). The qPCR reaction was performed by using the total reaction volume of 10 μL and the HCV viral load thermal cycling conditions were as follows: activation at 42°C for 2 minutes hold, 70°C for 1 minute hold, 95°C for 20 seconds and 45 cycles of 95°C 15 seconds and 55°C for 60 seconds. The PCR product was detected by using Quasar 670 dye (Q670).

Genotyping of IL28B Polymorphism (rs12979860): PCR was used to amplify the reverse complementary region by using a set of specific Forward Primers: (5’-CTCAGGGTCAATCACAGAAG-3’) and Reverse primers (5’-GAGGATGCAGAGAAGCTG-3’). Using online software, the primers flanking the polymorphic region were designed. (https://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). (Primer3 plus bioinformatics) The PCR product was amplified by using total volume of 25 μL comprising 7 μL of distilled water, 1 μL of each forward and reverse primers, a significant amount of 2.5 mm MgCl2 1.7 μL 2.5% of DMSO, 10 μL of Master mix (Mapleton Taq DNA polymerase 2x master mix catalog number A120301) and 4 μL of template DNA. The initial denaturation was allowed at 95°C for 5 minutes; then 35 cycles were performed with denaturation of 95°C for 30 seconds, annealing at 64.7°C for 30 seconds and extension at 72°C for 1.15 minutes. The final extension was carried out at 72° C for 5 minutes. Then further 10 μL amplified product was processed for RFLP at 37°C for 2 hours. By using restriction ensyme HPY1II6. A 10 μL amplified product was subjected to 2% electrophoresis to get the bands GG 467 bp, 132 bp, AA 467bp, 102bp and GA 467bp,132 bp and 102 bp fragments.

Statistical Analysis

Statistical analysis was carried out by using done by using open epi web tool, Microsoft excel and statistical analysis were done by using Statistical Package for the Social Sciences (SPSS) 25.0 version. The mean and standard deviation was used for age, aspartate transferase, Alanine transferase and their p-value was calculated by using t-test. The gender was calculated by using Chi-square test. Categorical variable were analysed by using in frequency, percentage and Chi-square test. Difference in IL28B genotype and allele between the cases and controls were compared by calculating p-value from Chi-square test. A p-value <0.05 was considered as significant.

Results

In the present study, all 248 participants were genotype for SNP rs 12979860 of IL28B gene, includes two groups, in cases 124 HCV positive patients and in controls, 124 controls. The mean age and standard deviation of cases 51.33±16.58 years and in control 50.61±16.21 years. In cases, males were 90 (72.6%) and females were 34 (27.4%) whereas in controls males were 83 (66.9%) and females were 41 (33.1%) and AST and ALT level described in (Table/Fig 1). The distribution of genotype and allele frequency of SNP rs 12979860 is described in (Table/Fig 2). In cases, the frequency of G/G genotype was considerably high 83 (67%) compared to G/A 17 (13.7%) and A/A 24 (19.3%) and in controls the frequency of G/G genotype 84 (67.7%), G/A genotype 34 (27.4%) and A/A genotype 6 (4.9%). The frequency of allele “G” was found to be considerably higher in both the cases and controls. It would be designated as major allele in the study group while “A” as minor allele. There was a statistically difference in both cases and controls (p=0.002 value). The genotype frequencies of the IL28 B (rs 12979860) variants were also analysed by adopting different models. The results are given in (Table/Fig 3). Both the variants showed the highest association with the multiplicative model. The genotype frequencies in the control group were in conformity with the Hardy-Weinberg equilibrium χ2=(2.6x10-14).

To assess the effect of the IL28B rs12979860 SNP on Hepatitis C infected patients (n=124) viral load, we quantified the viral load in the patients infected with HCV with different IL28B rs 12979860 genotypes as shown in (Table/Fig 4). The average (±SEM) HCV viral load was 4.6±3.6×107, 9.4±7.7×107 and 5.5±5.2×107 IU/mL in patients with the IL28B rs12979860 GG, GA and AA respectively. Moreover, the median and Interquartile range of viral load was 1675200 (43410-16928250), 203925 (35100-873150), 11736900 (4927500-30956775). Also there was a significance between the viral load and IL28B rs 12979860 (p-value <0.05).

Discussion

In patients infected with HCV, the connection between HCV RNA viral load and IL28B genotype studies are still limited. In this study, the effect of the IL28B rs12979860 SNP on HCV viral load was investigated. The IL28B genotype was discovered to be able to predict the outcome of HCV infection but not the HCV viral load. The most recent genome-wide association studies found a link between multiple SNPs in the IL28B gene (IFN-gene domain) and antiviral drug efficacy, with the SNP rs12979860(C/T) of the IL28B gene was particularly strong (12),(13). The ability to determine Sustained Virologic Response (SVR) in patients with HCV infection before beginning antiviral therapy is critical in determining the probability of therapeutic success.

The present study was an attempt to detect the viral load and their association with IL28B in hepatitis C infected patients. In this study, the reverse complementary polymorphic region of SNP 12979860(G/A) were studied. The frequency of allele G is significantly higher which act as a major allele but as compared to other studies they are considered C as a major allele. In present study the results showed that GG genotype 83 (67%) as compared to GA 17 (13.7%) and AA 24 (19.3%) and in control the frequency of GG genotype 84 (67.7%), GA genotype 34 (27.4%) and AA genotype 6 (4.9%) concordance with the previous study from Andhra Pradesh in the year 2012 (11).

In this study the frequency of G/G genotype was the highest 83 (67%) and there was a significant correlation found between the viral load and IL28B rs 12979860. Studies conducted in Indian subcontinent results were also correlated that IL28B is significant predictors of SVR with HCV genotype 1 and 3 (14). The CC genotype was discovered in 54.4% of patients, whereas the variant genotype (CT+TT) was detected in 45.6% of patients who had their rs12979860 IL28B genotypes determined. IL28B polymorphisms could be a key factor in modifying antiviral therapy for CHC patients by Khan MS et al., (15). These results were in coherence with the ones obtained by Sarrazin C et al., (16). They found a significant correlation between SVR and IL28B rs 12979860. The genotypes 2 and 3 were taken in their study. Also in another study it was also found that the patients having the HCV patients with the CC or TT genotypes are found to be having more viral load than the patient with CT/TT or TG/GG (17). In a study by Firdaus R et al., was also in favour that the genotype 3 infected patients; the rs12979860 CC genotype was markedly related with prolonged virological response. In patients with high viral load, CC genotypes at rs12979860 were observed to be linked with persistent virological response (OR=6.75, p-value <0.05) (18). A cohort study from India, also suggested that patients infected with genotype 3 and IL28B SNP is linked to both early viral decrease and long-term viral response (19). In the present study although there was such association observed apart from the finding that the highest percentage of patients consisted of GG genotype. The study finding the coherence with the present study was the one conducted by Abdelwahab SF et al., (20). They examined 375 Egyptians with genotype 4 and found out that there was no significant association between viral load and IL28B rs 12979860. When considering the SVR a study by Ge D et al., concluded that rate of SVR becomes two fold greater for the rs12979860 CC genotype when compared with the TT genotype (4). In another study by Rauch A et al., a considerable number of infected patients having genotype 2/3 also showed no correlation between the rs8099917 genotype and virological response to the compounded therapy of paginated interferon/ribavirin (21). This points towards the least correlation between the viral load and the IL28B rs 12979860. In another study in spain Labarga P et al., it was found that CC genotype was associated with the higher HCV viral load than all other genotypes (22). It can suggested that IL28B rs 12979860 plays a crucial role as determinant of baseline virological load and further there should be more studies on the polymorphism of IL28B to access the clinical outcomes and treatment response.

Limitation(s)

To better confirm the results of polymorphism study more number of samples are required. Further polymorphism study of IL28B with HCV genotypes and also follow-up study can also be helpful for future vaccine development.

Conclusion

This study concluded that, the IL28B rs12979860 SNP was found to be help in spontaneous clearance of infection in untreated HCV patients, it had effect on the viral load in infected patients. Since the GG genotype has been shown to be a strong predictor of HCV treatment clearance, extending the current findings to a larger study cohort should provide information for better HCV-mediated illness management in Indian participants. However, these findings highlight the importance of viral-host interactions in defining the course of HCV infection.

References

1.
Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001;33(2):455-63. [crossref] [PubMed]
2.
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Eng J Med. 1999;341(8):556-62. [crossref] [PubMed]
3.
Grebely J, Page K, Sacks Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109-20. [crossref] [PubMed]
4.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-01. [crossref] [PubMed]
5.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-01. [crossref] [PubMed]
6.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genetics. 2009;41(10):1105-09. [crossref] [PubMed]
7.
Bellanti F, Vendemiale G, Altomare E, Serviddio G. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clinical and Developmental Immunology. 2012;2012. [crossref] [PubMed]
8.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genetics. 2009;41(10):1100-04. [crossref] [PubMed]
9.
Griffiths SJ, Dunnigan CM, Russell CD, Haas JG. The role of interferon-λ locus polymorphisms in hepatitis C and other infectious diseases. J Innate Immun. 2015;7(3):231-42. [crossref] [PubMed]
10.
Sivaprasad S, Rao PN, Gupta R, Ashwini K, Reddy DN. The distribution of genotype and allelic frequency of IL28B gene polymorphism in Andhra Pradesh, India. J Clin Exp Hepatol. 2012;2(2):112-15. [crossref]
11.
Miller SA, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. [crossref] [PubMed]
12.
Shaheen M, Afzal S, Khubaib B, Amin I, Shahid M, Idrees M. Association of interleukin 28B polymorphism with clearance of Hepatitis C virus: A mini review. Crit Rev Eukaryot Gene Expr. 2020;30(3):223-29. [crossref] [PubMed]
13.
Ateya RM, Afifi SA, Abd Al Monem N, Al-Karamany SA, Bessar AA, Rageh F, et al. Impact of IL-28B gene polymorphism on chronic hepatitis-C patients progression with diabetes and non-diabetes. Egypt J Med Hum Genet. 2022;23. Doi: https://Doi.org/10.1186/s43042-022-00239-3. [crossref]
14.
Ranjan P, Fletcher GJ, Radhakrishnan M, Sivakumar J, Premkumar PS, Goel A, et al. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent. Indian J Med Microbiol. 2016;34(3):335-41. [crossref] [PubMed]
15.
Khan MS, Shoukat A, Mudassar S, Kawoosa Z, Shah AH, Zargar SA. Impact of IL28B genetic variant’s and viral genotype on treatment outcome of hepatitis C infected patients. J Infect Dev Ctries. 2018;12(09):762-70. [crossref] [PubMed]
16.
Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Heptol. 2011;54(3):415-21. [crossref] [PubMed]
17.
Rüstemoğlu A, Yalcin D, Günal Ö, Çelik B, Barut HS, Ateş HÖ. Interleukin 28B rs12979860 CT, rs12980275 GA, rs8099917 GT and TT genotypes are the predictors of rapid viral response in Hepatitis C Virus-infected patients. Viral Hepatitis Journal. 2016;22(3):97-102. [crossref]
18.
Firdaus R, Biswas A, Saha K, Mukherjee A, Chaudhuri S, Chandra A, et al. Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. PLoS One. 2014;9(6):e99126. [crossref] [PubMed]
19.
Chinnaswamy S, Das K, Bairagya BB, Bhattacharyya C, Duseja A, Amarapurkar D, et al. Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India. Tropical Gastroenterology. 2015;35(2):96-02. [crossref] [PubMed]
20.
Abdelwahab SF, Zakaria Z, Allam WR, Hamdy S, Mahmoud MA, Sobhy M, et al. Interleukin 28B. rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. Archives of Virology. 2015;160(11):2833-37. [crossref] [PubMed]
21.
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology. 2010;138(4):1338-45. [crossref] [PubMed]
22.
Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS. 2011;25(6):761-66. [crossref] [PubMed]

DOI and Others

DOI: 10.7860/JCDR/2022/56858.16711

Date of Submission: Apr 04, 2022
Date of Peer Review: May 07, 2022
Date of Acceptance: May 30, 2022
Date of Publishing: Aug 01, 2022

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Apr 11, 2022
• Manual Googling: May 27, 2022
• iThenticate Software: Jun 01, 2022 (18%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com